Nyxoah
Mont-Saint-Guibert, Walloon Brabant, Belgium · Biotechnology, Health Care, Manufacturing
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA's innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world's most common sleep disordered breathing condition.
Key facts
- Headquarters
- Mont-Saint-Guibert, Walloon Brabant, Belgium
- Employees
- 51
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (NYXH)
- Website
- nyxoah.com
- Company page
Recent activity at Nyxoah
- : Nyxoah SA Appoints Liam Kelly as Chief Executive Officer
- : Nyxoah Appoints John Landry as Chief Financial Officer, Loïc Moreau to Transition into Role of President International
- : Nyxoah Appoints Scott Holstine as Chief Commercial Officer
- : Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
- : Nyxoah Appoints Francis Kim as Chief Regulatory, Quality Officer
Leadership
- Liam Kelly, Chief Executive Officer
- Loïc Moreau, President
- John Landry, Chief Financial Officer
- Scott Holstine, Chief Commercial Officer
- Olivier Taelman, Chief Executive Officer
- Maurits S. Boon, Chief Medical Officer
- Francis Kim, Chief Regulatory
Verified email and direct lines for Nyxoah’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Nyxoah in the news
- Nyxoah Appoints Liam Kelly as Chief Executive Officer - GlobeNewswire (Sep 28, 2026)
- Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary - GlobeNewswire (Sep 02, 2026)
- Healthtech company Nyxoah makes debut on Euronext Brussels - Euronext (Sep 20, 2020)
- Nyxoah to Host Investor Day in New York on July 8, 2026 - GlobeNewswire (Jun 23, 2026)
- Nyxoah Announces Preliminary Results for the Second Quarter of 2026 - GlobeNewswire (Jul 07, 2026)
- Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology - GlobeNewswire (Jun 15, 2026)
- Nyxoah Announces Chief Financial Officer Transition - GlobeNewswire (Sep 21, 2026)
- Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System - GlobeNewswire (Sep 07, 2026)
Companies similar to Nyxoah
- Encision · Biotechnology, Health Care, Manufacturing
- Medu Group · Biotechnology, Health Care, Manufacturing
- Medical Optics · Biotechnology, Health Care, Manufacturing
- Anja Health · Biotechnology, Health Care, Manufacturing
- Paradigm Spine GmbH · Biotechnology, Health Care, Manufacturing
About Nyxoah: questions and answers
What does Nyxoah do?
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA's innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world's most common sleep disordered breathing condition.
Where is Nyxoah headquartered?
Nyxoah is headquartered in Mont-Saint-Guibert, Walloon Brabant, Belgium.
How many employees does Nyxoah have?
Nyxoah has about 51 employees.
Who leads Nyxoah?
Liam Kelly is a Chief Executive Officer at Nyxoah.
What is the latest news on Nyxoah?
On Sep 30, 2026, Nyxoah SA Appoints Liam Kelly as Chief Executive Officer
Is Nyxoah a public company?
Yes. Nyxoah is publicly traded under the ticker NYXH.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy